← Back to Screener
Haemonetics Corporation (HAE)
Price$61.17
Favorite Metrics
Price vs S&P 500 (26W)14.87%
Price vs S&P 500 (4W)-3.50%
Market Capitalization$2.83B
P/E Ratio (Annual)16.89x
All Metrics
P/CF (Annual)15.58x
Book Value / Share (Quarterly)$19.46
P/TBV (Annual)8.74x
Revenue Growth (3Y)11.07%
Cash Flow / Share (Quarterly)$5.49
Price vs S&P 500 (YTD)-27.61%
Gross Margin (TTM)59.32%
Net Profit Margin (TTM)13.31%
EPS (TTM)$3.64
10-Day Avg Trading Volume0.64M
EPS Excl Extra (TTM)$3.64
Revenue Growth (5Y)6.60%
EPS (Annual)$3.31
ROI (Annual)8.20%
Gross Margin (Annual)56.11%
Net Profit Margin (5Y Avg)8.93%
Cash / Share (Quarterly)$7.76
P/E Basic Excl Extra (TTM)16.14x
Revenue Growth QoQ (YoY)-2.75%
EPS Growth (5Y)17.48%
P/E Normalized (Annual)16.89x
ROA (Last FY)6.84%
Revenue Growth TTM (YoY)-4.02%
EBITD / Share (TTM)$6.15
ROE (5Y Avg)12.69%
Operating Margin (TTM)19.05%
Cash Flow / Share (Annual)$2.52
P/B Ratio3.11x
P/B Ratio (Quarterly)4.14x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.80x
Net Interest Coverage (TTM)22.76x
ROA (TTM)7.13%
EPS Growth QoQ (YoY)28.61%
EV / EBITDA (TTM)12.48x
EPS Incl Extra (Annual)$3.31
Current Ratio (Annual)1.62x
Quick Ratio (Quarterly)1.04x
3-Month Avg Trading Volume0.81M
52-Week Price Return7.00%
EV / Free Cash Flow (Annual)30.44x
P/E Incl Extra (TTM)16.14x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$10.50
P/S Ratio (Annual)2.08x
Asset Turnover (Annual)0.56x
52-Week High$87.32
Operating Margin (5Y Avg)12.14%
EPS Excl Extra (Annual)$3.31
CapEx CAGR (5Y)4.35%
Tangible BV CAGR (5Y)-4.27%
26-Week Price Return21.76%
Quick Ratio (Annual)0.88x
13-Week Price Return-17.34%
Total Debt / Equity (Annual)1.49x
Current Ratio (Quarterly)1.75x
Enterprise Value$3,693.33
Revenue / Share Growth (5Y)7.05%
Asset Turnover (TTM)0.54x
Book Value / Share Growth (5Y)7.84%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.75x
Pretax Margin (Annual)15.58%
Cash / Share (Annual)$6.36
3-Month Return Std Dev33.11%
Gross Margin (5Y Avg)52.65%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)4.79%
EBITDA Interim CAGR (5Y)5.02%
ROE (Last FY)20.43%
Net Interest Coverage (Annual)10.49x
EPS Basic Excl Extra (Annual)$3.31
P/FCF (TTM)11.02x
Receivables Turnover (TTM)6.47x
EV / Free Cash Flow (TTM)14.37x
Total Debt / Equity (Quarterly)1.34x
EPS Incl Extra (TTM)$3.64
Receivables Turnover (Annual)6.65x
ROI (TTM)8.39%
P/S Ratio (TTM)2.15x
Pretax Margin (5Y Avg)10.81%
Revenue / Share (Annual)$26.82
Tangible BV / Share (Annual)$7.57
Forward P/E12.37x
Free OCF CAGR (5Y)2.09%
Price vs S&P 500 (52W)-27.64%
P/E Ratio (TTM)16.14x
EPS Growth TTM (YoY)43.23%
Year-to-Date Return-23.68%
5-Day Price Return1.14%
EPS Normalized (Annual)$3.31
ROA (5Y Avg)4.97%
Net Profit Margin (Annual)12.32%
Month-to-Date Return8.53%
Cash Flow / Share (TTM)$4.33
EBITD / Share (Annual)$5.32
EPS Growth (3Y)57.60%
Operating Margin (Annual)16.30%
LT Debt / Equity (Annual)1.12x
P/CF (TTM)8.36x
ROI (5Y Avg)6.10%
P/E Excl Extra (TTM)16.14x
LT Debt / Equity (Quarterly)1.01x
EPS Basic Excl Extra (TTM)$3.64
P/TBV (Quarterly)7.67x
P/B Ratio (Annual)3.89x
Inventory Turnover (TTM)1.58x
Pretax Margin (TTM)17.23%
Book Value / Share (Annual)$17.02
Price vs S&P 500 (13W)-19.72%
Net Margin Growth (5Y)9.74%
Beta0.54x
P/FCF (Annual)23.34x
Revenue / Share (TTM)$28.06
ROE (TTM)20.26%
52-Week Low$47.31
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
3.93
3.93
3.93
3.93
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
HAEHaemonetics Corporation | 2.15x | 6.60% | 59.32% | 19.05% | $61.17 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Haemonetics provides medical solutions for blood and plasma collection, processing, and transfusion services across three business segments: plasma, blood center, and hospital. The plasma and hospital segments drive growth due to robust market potential, while the blood center segment faces competitive headwinds. Revenue is generated through sales of disposable collection and processing sets and supporting equipment.